AT-511
| CAS No. | 1998705-64-8 | Cat. No. | BCP43134 |
| Name | AT-511 | ||
| Synonyms | AT511; AT 511; Bemnifosbuvir; | ||
| Formula | C24H33FN7O7P | M. Wt | 581.53 |
| Description | AT-511, the free base form of AT-527, against several coronaviruses, including SARS-CoV-2, the causative agent of COVID-19. In normal human airway epithelial (HAE) cell preparations, the average concentration of AT-511 required to inhibit replication of SARS-CoV-2 by 90% (EC90) was 0.5 µM, very similar to the EC90 for AT-511 against HCoV-229E, HCoVOC43 and SARS-CoV in Huh-7 cells. No cytotoxicity was observed for AT-511 in any of the antiviral assays up to the highest concentration tested (100 µM). Surprisingly, AT-511 was 30-fold less active against MERS-CoV. | ||
| Pathways | Microbiology/Virology | ||
| Targets | SARS CoV | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.